Group 1 - The company announced a focused restructuring aimed at enhancing profitability and increasing returns across its portfolio [3] - The new Chief Scientific Officer, Dr. Patrik Foerch, has over 20 years of experience in immunology, oncology, and neuroscience, and will focus on driving the research pipeline [2] - The restructuring follows a comprehensive review of the company's pipeline to support near-term value creation [3]